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Abstract 
Sarcopenia as a progressive and generalized skeletal muscle disorder that is associated with an 
increased likelihood of adverse outcomes, including falls, fractures, physical disability, and mortality. 
On the other hand, an age-related decline in muscle strength prior to the reduction of muscle mass, is 
proposed to be “dynapenia”. Sarcopenia and dynapenia, has recently been recognized as a diabetic 
complication in type 2 diabetes. We firstly indicated that sarcopenia was frequently observed in 
16.6% of patients with type 1 diabetes aged even over 40 years. Additionally, we recently reported 
that the prevalence rate of dynapenia was higher than sarcopenia in patients with type 2 diabetes. 
Chronic hyperglycemia also accelerates accumulation of advanced glycation end products (AGEs), 
which causes diabetic vascular complications through oxidative stress and chronic inflammation. We 
also demonstrated that skin autofluorescence (AF) as a marker of AGEs, was the independent 
determinant for skeletal muscle mass and strength in patients with type 2 diabetes and muscle 
strength in type 1 diabetes. Therefore, the early diagnosis of muscle weakness is essential for patients 
with diabetes and sustained good glycemic control with exercise and dietary intervention might be 
beneficial to prevent the progression of muscle weakness in these patients. 
 
Sarcopenia and Dynapenia 
Pandemic increase in the number of elderly patients with diabetes mellitus is a social and 
economic burden, as well as a medical issue. Elderly patients with diabetes mellitus have multiple 
complications, such as advanced vascular disease and impaired cognitive function. Recently, 
ageing-related muscle weakness, so-called sarcopenia, has been recognized as a diabetic 
complication and frequently increases the incidence of falls and frailty in these patients [1,2]. 
Sarcopenia was proposed as an ageing-related loss of muscle mass and function by Rosenberg IH in 
1988 [3].  
On the other hand, Clark BC and Manini TM proposed that an ageing-related decline in muscle 
strength prior to the reduction of muscle mass should be described as “dynapenia” [4]. To evaluate 
muscle strength, they recommended knee extension strength as well as grip strength simultaneously. 
‘Sarcopenia’ should be used in its original context, the loss of skeletal muscle mass, while the term 
‘dynapenia’ should be used to represent the impaired muscle strength without loss of skeletal muscle 
mass.  
We observed a high prevalence rate of low knee extension strength as well as sarcopenia in type 1 
diabetes [5]. Moreover, we recently reported that the prevalence rate of dynapenia was higher than 
sarcopenia in patients with type 2 diabetes [6]. In addition, the prevalence of poor muscle strength 
has been found to be higher in patients with type 1 and 2 diabetes, than in the general elderly 
Japanese population [7]. Taken together, muscle strength could be impaired prior to reduced muscle 
mass in patients with type 1 and 2 diabetes.  
  
New definition of sarcopenia: EWGSOP2 
The definition of sarcopenia was established by the European Working Group on Sarcopenia in 
Older People (EWGSOP) [8] and the Asian Working Group of Sarcopenia (AWGS) in 2010 and 
2014, respectively [9]. EWGSOP defines sarcopenia as a progressive and generalized skeletal muscle 
disorder that is associated with an increased likelihood of adverse outcomes, including falls, fractures, 
physical disability, and mortality [10-12]. In these criteria, sarcopenia is identified by decreased 
muscle mass accompanied by decreased grip strength or gait speed. The determinants for sarcopenia, 
proposed by EWGSOP and AWGS, are hand grip strength, gait speed, and skeletal muscle mass 
index (SMI). An updated definition of sarcopenia proposed by EWGSOP2 in 2018 (Fig 1) [13],  
added the chair stand test, instead of gait speed, as indicator of muscle strength, and the gait speed 
was categorized as measurement tool of physical performance in clinical practice. Hand grip strength 
has been widely used as a diagnostic criterion and correlates well with most relevant outcomes. 
Although the diagnostic criteria of AWGS and EWGSOP did not include lower limb muscle 
weakness [8,9], the chair stand test were added to evaluate the lower limb muscle weakness in 
clinical practice in EWGSOP2 [13]. Since the cost, availability, and usability are important to 
determine measurement tools in clinical practice, the chair stand test is better indicator than accurate 
knee flexion/extension measurement tools which is necessary to use special equipment and training.  
 
Sarcopenia and diabetes 
According to AWGS criteria, the prevalence of sarcopenia is 4-11% in Asian individuals over 65 
years old, whereas 11-15% in patients with type 2 diabetes [6,14,15]. We also indicated that 
sarcopenia was frequently observed even in 16.6% of patients with type 1 diabetes aged over 40 
years [5]. In addition, many of these patients presented with reduced muscle function, involving 
lower SMI and limb muscle strength. The influence of type 1 diabetes on skeletal muscle mass has 
been analyzed in humans and rodent’s models [16,17]. These results clearly showed that type 1 
diabetes was associated with impaired skeletal muscle mass and strength. Hormonal changes of 
decreased insulin and IGF-1 signaling, and increased glucocorticoid were speculated to contribute to 
muscle atrophy in these patients. Recent study also revealed that hyperglycemia itself reduces muscle 
mass via increase of KLF15 in myocyte [18]. Therefore, patients with diabetes are possible 
candidates for disease-related sarcopenia. Since hyperglycemia itself has been proposed to be a 
contributor of sarcopenia, treatment for diabetes could be preferable to prevent and attenuate muscle 
dysfunction accompanied with diabetes. In addition, treatment with insulin [19] and DPP-4 inhibitor 
[20] were reported to attenuate progression of sarcopenia in patients with type 2 diabetes. In addition, 
sodium-glucose cotransporter 2 (SGLT2) inhibitor also reported to increase hand grip strength [21], 
but several reports have been showed SGLT2 inhibitor decrease muscle mass as well as fat mass, 
Therefore, the further studies need to clarify this issue. 
 
Dynapenia and diabetes 
Dynapenia, characterized by muscle mass weakness independent of muscle mass, was defined 
according to the proposed criteria based on low hand grip strength and knee extension strength with 
normal SMI (Fig 2) [4]. When the sarcopenia components were examined individually, only a low 
muscle strength was associated with the incidence of recurrent falling, independent of low muscle 
mass or slow gait speed [22]. Therefore, in elderly individuals, muscle strength could be more 
beneficial tool to evaluate physical condition than gait speed and muscle mass. The previous report 
showed that hyperglycemia evaluated by glycated hemoglobin (HbA1c) is associated with the 
weakness of muscle strength independently with muscle mass [23]. Additionally, the decline in 
muscle strength in highest quartile of HbA1c groups seemed to start at 40's years old. This suggests 
that hyperglycemia-associated muscle weakness could start at an early stage of diabetes. Our study 
shows that sarcopenia and dynapenia were observed in elderly patients with a longer duration of 
diabetes, and the difference between the clinical characteristics of these comorbidities was adiposity, 
indicated by BMI, %fat, and visceral fat area [6]. Sarcopenic patients showed low BMI, whereas in 
dynapenia patients BMI was comparable to that in patients without sarcopenia and dynapenia. A 
previous study showed that obese patients with type 2 diabetes had lower muscle strength than 
healthy subjects with normal body weight [2]. The accumulation of intramuscular fat is inversely 
associated with lower-limb muscle function in elderly individuals [24]. On the other hand, increased 
body weight could be detrimental to the maintenance of muscle volume. Indeed, a high %body fat 
was significantly, and independently, associated with the risk of dynapenia in patients with type 2 
diabetes in our study. Elderly, obese patients with type 2 diabetes may therefore have a higher 
prevalence of dynapenia, but not sarcopenia. Diabetic polyneuropathy might cause a decline in lower 
extremity strength in middle-aged and elderly type 2 diabetes patients [25]. In addition, 38.8% to 
62.4% of patients with type 2 diabetes aged ≥ 65 years demonstrated low hand grip and knee 
extension strength, respectively, in our study, and this prevalence was higher than that found in the 
general elderly Japanese population [7]. It is possible that type 2 diabetes may lead to muscle 
weakness at a younger age than the general population. Therefore, the typical characteristics of 
muscle dysfunction in elderly patients with type 2 diabetes could be lower muscle strength in the 
extremities, but not a decrease in muscle volume compared to subjects without type 2 diabetes. 
Furthermore, impaired knee extension strength was observed frequently even in patients under 65 
years old, suggesting that muscle strength of lower limb could be a better indicator of muscle 
dysfunction than grip strength, in patients with type 2 diabetes. So, a clear definition of dynapenia 
will provide a better understanding of the role that dynapenia plays in the loss of physical function 
and increased risk for disability among older adults. 
 
Advanced glycation end products and Sarcopenia and Dynapenia in diabetes 
Advanced glycation end products (AGEs) accumulate with ageing in various human tissues. 
Chronic hyperglycemia also accelerates AGEs accumulation, which causes diabetic vascular 
complications such as macro- and micro-angiopathy through oxidative stress and chronic 
inflammation [26]. As well as a longer duration of diabetes, sustained hyperglycemia is thought to 
contribute to muscle weakness in patients with diabetes [23]. AGEs have been identified in ageing 
human skeletal muscle. Skin autofluorescence (AF), indicator of accumulated AGEs in the skin, is 
known to reflect the integration of long-term glycemic control over the past 15 years, but not current 
glycemic control, in patients with type 1 diabetes [27]. We previously indicated that skin AF was 
inversely associated with low knee extension strength in type 1 and 2 diabetes patients using an 
adjusted multivariate logistic regression model [5,6]. Skin AF was also inversely associated with low 
SMI in type 2 diabetes patients using this model. Recent study in the rodent demonstrated that AGEs 
induced muscle atrophy and muscle dysfunction via AGE receptor-mediated AMPK-downregulation 
of the Akt signaling pathway [28]. Therefore, ageing and sustained hyperglycemia accumulate AGEs 




Patients with type 1 and type 2 diabetes are possible candidates for dynapenia as well as 
disease-related sarcopenia. In addition, we revealed that the weakness of knee extension strength was 
highly associated with accumulation of AGE even under 65 years old in the both type of diabetes. 
Therefore, chronic hyperglycemia-associated decline of muscle strength begins at younger stage of 
type 1 and type 2 diabetes. Therefore, the early diagnosis of muscle weakness is essential for patients 
with diabetes and sustained good glycemic control with exercise and dietary intervention might be 
beneficial to prevent the progression of muscle weakness in these patients. 
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Fig. 1 Figure 1. Updated algorithm for sarcopenia case-finding, diagnosis and severity determination 
by EWGSOP2 (DXA:Dual energy X-ray absorptiometry, BIA:Bioelectrical impedance analysis , 
SMI: skeletal muscle mass index , TUG: timed up and go test, SPPB: short physical performance 
battery )  
Fig 2. Algorithm for diagnosis of dynapenia 
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